HITV Lab

Call Us : +603-9010-3058
Email Us : This email address is being protected from spambots. You need JavaScript enabled to view it.

You are here: Home Publications, News & Events News & Events

Thursday29 June 2017

Sabah New Times : Cancer Cure Is Now In Malaysia

TMM

KUALA LUMPUR : There is a new hope for cancer patients in Malaysia. A vaccine widely known for treating late-stage cancer -- almost all types of cancer, except leukemia -- is now available in the country.

The Human Initiated Therapeutic Vaccine (HITV), which was only available in Japan previously, is able to completely destroy microscopic and tiny nests of cancer cells, thus preventing any future recurrences.

Discovered in 2005 by Dr Kenichiro Hasumi, a Japanese physician and researcher, HITV is an autologus (patient derived) active cell-based immunotherapy for metastatic or late-stage cancer patients.

It is based on immunology that harnesses human immune system's innate and adaptive ability to combat diseases.

Read more ...

New Straits Times : Hope for late-stage cancer patients

NST

KUALA LUMPUR : There is still hope for late-stage cancer patients as treatment that could help cure the disease is now available in the country.

The Human Initiated Therapeutic Vaccine (HITV) Therapy, previously available only in Japan, has been brought to Malaysia through the Mahameru International Medical Centre.

Dr Kenichiro Hasumi, founder and president of the Hasumi International Research Foundation, said HITV is an autologous (patient-derived) active cell-based immunotherapy.

He said a HITV study on 26 patients with different advanced cancers showed 80 per cent of the patients demonstrated a complete response to the initial treatment, while 50 per cent have remained disease-free.

Read more ...

HITV Lab

HITV Lab is involved in cell-based biotechnology medical applications with special focus on Dendritic Cell-Based Immunotherapy for cancer. HITV Lab is committed to support an international collaboration in the FDA clinical trial of HITV Therapy in late-stage cancer patients led by the University of Maryland, USA.

FacebookTwitterGoogle Bookmarks